Context Therapeutics, Inc. (CNTX)
0.3042
+0.01
(+1.74%)
USD |
NASDAQ |
Oct 09, 16:00
0.29
-0.01
(-4.67%)
After-Hours: 20:00
Context Therapeutics Enterprise Value : -14.80M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | -14.80M |
| October 08, 2026 | -15.27M |
| October 07, 2026 | -14.02M |
| October 06, 2026 | -13.18M |
| October 05, 2026 | -11.83M |
| October 02, 2026 | -14.29M |
| October 01, 2026 | -13.86M |
| September 30, 2026 | -15.14M |
| September 29, 2026 | -13.44M |
| September 28, 2026 | -12.77M |
| September 25, 2026 | -10.98M |
| September 24, 2026 | -8.649M |
| September 23, 2026 | -7.592M |
| September 22, 2026 | -6.995M |
| September 21, 2026 | -8.328M |
| September 18, 2026 | -8.925M |
| September 17, 2026 | -7.519M |
| September 16, 2026 | -7.923M |
| September 15, 2026 | -9.265M |
| September 14, 2026 | -10.50M |
| September 11, 2026 | -10.55M |
| September 10, 2026 | -9.081M |
| September 09, 2026 | -8.750M |
| September 08, 2026 | -8.171M |
| September 04, 2026 | -9.513M |
| Date | Value |
|---|---|
| September 03, 2026 | -9.393M |
| September 02, 2026 | -9.421M |
| September 01, 2026 | -9.274M |
| August 31, 2026 | -6.940M |
| August 28, 2026 | -7.491M |
| August 27, 2026 | -4.514M |
| August 26, 2026 | -3.816M |
| August 25, 2026 | -2.741M |
| August 24, 2026 | 0.0152M |
| August 21, 2026 | 3.203M |
| August 20, 2026 | 5.004M |
| August 19, 2026 | 2.046M |
| August 18, 2026 | 2.873M |
| August 17, 2026 | 5.978M |
| August 14, 2026 | 5.298M |
| August 13, 2026 | 3.782M |
| August 12, 2026 | 0.4286M |
| August 11, 2026 | 0.0519M |
| August 10, 2026 | -1.188M |
| August 07, 2026 | 1.724M |
| August 06, 2026 | 3.562M |
| August 05, 2026 | 20.93M |
| August 04, 2026 | 14.39M |
| August 03, 2026 | 12.76M |
| July 31, 2026 | 12.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck & Co., Inc. | 406.21B |
| ANI Pharmaceuticals, Inc. | 1.932B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 18.84M |
| Johnson & Johnson | 657.89B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.56M |
| Total Expenses (Quarterly) | 14.56M |
| EPS Diluted (Quarterly) | -0.153 |
| Earnings Yield | -160.4% |
| Normalized Earnings Yield | -160.36 |